TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02139709

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ganglioside
Study: NCT01059578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK206136
Description: GSK206136 2mg, 10mg, 50mg, 100mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET
Description: Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
Study: NCT00582660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: 400 mg twice a day for 7 days prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet of placebo will be given for 7 days prior to surgery
Study: NCT03068039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oats breakfast porridge
Description: Isoenergetic and isovolumteric oats breakfast porridge
Study: NCT02139709

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02853903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NK immunotherapy
Description: Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
Study: NCT00458601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-110 with GM-CSF
Description: Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
Study: NCT03068039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pearl (bajra) breakfast porridge
Description: Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
Study: NCT00900822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straumann Bone Ceramic
Description: Granules applied once during surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioOss
Description: Granules that are applied once during surgery
Study: NCT01917292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-Stage Full-Mouth Disinfection
Description: 1. Basic oral hygiene instructions~2. Dental extractions will be performed (only in cases of teeth that could not be saved)~3. Standard cycle of supragingival ultrasonic scaling and polishing~4. Scaling and root planning after the administration of local anesthesia, four quadrants in one session~5. Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal care
Description: 1. Basic oral hygiene instructions~2. Standard cycle of supragingival ultrasonic scaling and polishing
Study: NCT03697031

Intervention type: DRUG
Intervention: Follitropin Delta
Description: The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms.
Study: NCT03892499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olinciguat
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Capsule
Study: NCT02444910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT501
Description: 600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
Study: NCT02494167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiTAA-specific T cells
Description: The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart.
Study: NCT03356327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actitan F
Description: A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Oral Rehydration
Description: Standard oral rehydration as suggested by ESPGHAN guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Oral Rehydration
Description: Standard oral rehydration as suggested by ESPGHAN guidelines
Study: NCT02363699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
Study: NCT02363699

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
Study: NCT03744299

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patients and caregivers are asked to complete a questionnaire
Study: NCT02110784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eurartesim tablets
Description: dosage bands: 24 to \<36 kg body weight: 2 tablets a day for three consecutive days 36 to \<75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
Study: NCT03758716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825, FB825-15D11, Anti-CemX
Description: Pharmaceutical form: 20mg/ml solution Route of administration: IV
Study: NCT03237338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ture acupuncture
Description: ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks
Study: NCT02180854

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased monitoring frequency
Study: NCT01849289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Study: NCT03237338

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks
Study: NCT01329913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6325
Description: Eight 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Eight 100 mg capsules, orally, once per day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-6325
Description: Eight 100 mg capsules, orally, once per day for 7 days
Study: NCT04302064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen administered SC
Study: NCT01849289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
Study: NCT03259607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Extra Mint 2 mg Gum
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Mint 2 mg Gum
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Extra Mint 4mg Gum
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Mint 4 mg Gum
Description: A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
Study: NCT02555722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fanfilcon A (test)
Description: silicone hydrogel lens
Study: NCT04302064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplontersen-matching placebo administered SC
Study: NCT02555722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A (control)
Description: silicone hydrogel lens
Study: NCT04723342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab, intravenously, as continuous 24 hours infusion 1-7 days - 5 μg/m2/day, 8-28 day - 15 μg/m2/day~1 course after induction treatment
Study: NCT01416259

Intervention type: DRUG
Intervention: Withdraw treatment
Study: NCT04043676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: All patient will take 15 mg/day ponatinib oral during 48 weeks.
Study: NCT04241627

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell Phone Support
Description: Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell Phone Support
Description: Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell Phone Support
Description: Cell Phone Support includes short phone calls (\<5 minutes) made each weekday by a human AF to provide social support, medication reminders, problem-solving coaching, incentives for answering calls, and referrals to other services. Cell Phone Support calls focus on assisting AYAs in identifying and accessing resources and support from their natural environments, such as finding ways they can receive needed help from their families, peers, medical teams, and communities. Live Text Support will deliver the same intervention, by text message.
Study: NCT00702949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT00572858

Intervention type: PROCEDURE
Intervention: Blood test
Description: for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen

Intervention type: GENETIC
Intervention: Blood test
Description: Blood test for genetic testing

Intervention type: PROCEDURE
Intervention: Ultrasound of neck arteries
Description: Non-invasive test using ultrasound waves to measure the thickness of the arteries

Intervention type: PROCEDURE
Intervention: Saliva test
Description: Saliva test for cotisol levels
Study: NCT02359942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citric acid
Description: Giving the citric acid (4g) solving in 200 ml of water before UBT
Study: NCT03942536

Intervention type: OTHER
Intervention: Focus Group Discussion
Description: At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
Study: NCT02166541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCSK
Description: The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BCSK
Description: The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional spinal manipulation
Description: Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional spinal manipulation
Description: Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INRS
Description: The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: INRS
Description: The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INRS
Description: The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy.
Study: NCT03532217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V
Description: -Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F
Description: -Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Nivolumab is a human monoclonal antibody (mAb)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: -Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Description: Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriGrid Delivery System
Description: -Electroporation device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: -Pre-treatment, post-treatment A (optional), and end of treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal samples
Description: -Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: * Post-treatment A/pre-treatment B~* Mid-Treatment B, after Cycle 9 Day 1 and prior to Cycle 10 Day 1~* End of treatment
Study: NCT02388542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
Study: NCT02737514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation
Description: Insufflation during colonoscopy including insertion phase
Study: NCT01727791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
Study: NCT02871089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop system (Florence M or CamAPS FX)
Description: The automated closed-loop system (FlorenceM) will consist of:~* Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~* An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~* Dana R or RS insulin pump~* Dexcom G6 real-time CGM~* CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Daily Injections
Description: Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed.
Study: NCT02981966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: dapagliflozin, 10mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: dapagliflozin, 10mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dapagliflozin
Study: NCT02737514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water immersion
Description: Water will infused during insertion phase and removed during withdrawal phase of colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: water exchange
Description: Water will infused and removed during insertion phase of colonoscopy
Study: NCT01068977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Repeating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetMAb
Description: Repeating escalating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetMAb
Description: Repeating escalating intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetMAb
Description: Repeating intravenous dose
Study: NCT02981966

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dapagliflozin